Skip to main content
SHINIL PHARMACEUTICAL CO., LTD. logo

SHINIL PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 012790 ISIN · KR7012790002 KO Manufacturing
Open in API
Filings indexed 197 across all filing types
Latest filing 2026-03-26 Declaration of Voting R…
Country KR South Korea
Listing KO 012790

About SHINIL PHARMACEUTICAL CO., LTD.

https://shinilpharma.com/

SHINIL PHARMACEUTICAL CO., LTD. is a drug manufacturing company that develops, produces, and sells a diverse range of pharmaceutical products. The company's portfolio encompasses various therapeutic areas, including vitamins, mineral supplements, anti-inflammatory enzymes, antihistamines, appetite stimulants, and treatments for liver disease. Its product offerings also include topical medications such as gels and medicated plasters. The company serves both domestic and international markets.

Recent filings

Filing Released Lang Actions
[기재정정]정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a corrected (“정정신고”) disclosure of the results (“결과”) of the company’s regular shareholders’ meeting (정기주주총회). It provides vote outcomes on approval of the financial statements, dividend resolutions, election of directors/auditors, and vote tallies. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-03-26 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a Korean-language notice detailing the results of the company’s Annual General Meeting held on 2026-03-26, including approved agenda items and vote percentages. It reports the outcome of shareholder votes, which corresponds exactly to a Declaration of Voting Results & Voting Rights Announcement.
2026-03-26 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Shinil Pharmaceutical Co., Ltd. It includes the independent auditor's opinion, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. It covers the fiscal years 2024 and 2025. This is a comprehensive financial audit document, not an annual report (10-K) which would include management discussion and analysis (MD&A) and other corporate disclosures, nor is it a short announcement (RPA). Therefore, it is classified as an Audit Report. FY 2025
2026-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 99% confidence The document is a regulatory filing from Shinil Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion, key financial data (assets, liabilities, revenue, profit), and auditor information for the fiscal year ending 2025-12-31. While it contains audit-related information, it is a standard regulatory disclosure announcement (DART filing) summarizing the audit results rather than the full, multi-page audit report document itself. Given the structure and content, it fits the 'Audit Report / Information' category as it provides the specific audit opinion and financial summary required by regulators. FY 2025
2026-03-17 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Sinil Pharmaceutical. It contains the agenda for the upcoming Annual General Meeting (AGM), including proposals for financial statement approval, director and auditor compensation limits, and information regarding electronic voting. While it contains financial data (balance sheets, income statements) as part of the meeting agenda, the primary purpose of the document is to solicit shareholder participation and provide the necessary information for the upcoming meeting. This aligns with the definition of a Proxy Solicitation & Information Statement (PSI).
2026-03-10 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Shinil Pharmaceutical. It outlines the date, location, agenda items (such as financial statement approval and director remuneration), and voting procedures. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of upcoming meeting details and agenda items, which falls under the PSI category.
2026-03-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.